Background
==========

Across the MVC development program, patients who received MVC-containing regimens experienced greater increases in CD4+ cell counts than those observed in comparator arms in primary analyses. Here we present longer term immunological data from this program.

Material and methods
====================

Long-term (96 week) data from subjects with CCR5-tropic HIV infection in the following ongoing MVC studies were included in the analysis: (1) MOTIVATE study (MVC QD and BID vs placebo (PBO), each combined with optimized background therapy in treatment-experienced \[TE\] subjects); and (2) MERIT study (MVC BID vs EFV, each combined with ZDV/3TC in treatment-naïve \[TN\] subjects). Additionally, interim week 24 data from the ongoing 96-week 1078 study (MVC QD vs TDF/FTC, each combined with ATV/r in TN subjects) were summarized. Descriptive statistics are presented for data at baseline and at week 96 (MERIT/MOTIVATE) or week 24 (1078) pertaining to change in CD4+ and CD8+ cells.

Results
=======

Greater increases in CD4+ cells in MVC-containing groups persisted through 96 weeks in the MOTIVATE and MERIT studies, and through 24 weeks in the 1078 study (Table [1](#T1){ref-type="table"}). Similarly, changes in CD8+ cells from baseline to weeks 96 or 24 favored MVC-containing regimens in all three studies. In a combined LOCF analysis of patients from all three studies at week 24, CD4+ counts increased by a median 100.5 cells/µL in 1260 recipients of MVC-containing regimens, compared with 84.5 cells/µL in 631 recipients of comparator regimens; CD8+ counts increased by a median 153 cells/µL in the MVC group, compared with a decrease of 61 cells/µL in the comparator group. At week 96, a combined analysis of patients from the MOTIVATE and MERIT studies showed median CD4+ increases from baseline of 129.5 and 100.3 cells/µL in the MVC (N=1177) and comparator (N=554) groups, respectively; CD8+ changes were 96 and -72 cells/µL, respectively. In all studies, differences in CD4+ and CD8+ counts between treatment groups were independent of differences in viral load changes (data not shown).

  Population                              Treatment-experienced      Treatment-naive                                                                     
  --------------------------------------- -------------------------- ----------------------- ---------------------- ------------- --------- ------------ -------------
  **Study**                               **MOTIVATE -- 96 Weeks**   **MERIT -- 96 Weeks**   **1078 -- 24 Weeks**                                        
                                                                                                                                                         
  **Arm**                                 **MVC QD**                 **MVC BID**             **PBO**                **MVC BID**   **EFV**   **MVC QD**   **TDF/FTC**
                                                                                                                                                         
  **N**                                   **414**                    **426**                 **209**                **360**       **361**   **60**       **61**
                                                                                                                                                         
  BL HIV RNA (median log~10~ cp/mL)       4.86                       4.85                    4.86                   4.88          4.85      4.59         4.66
                                                                                                                                                         
  Baseline CD4 count (median cells/µL)    171                        167                     171                    244.3         258.5     344.5        358.0
                                                                                                                                                         
  Baseline CD8 count (median cells/µL)    867.5                      836.5                   820.8                  791.5         860.0     859.8        890.0
                                                                                                                                                         
  CD4 change from BL (median cells/µL)    89.0                       112.5                   21.0                   224.3         195.0     195.3        173.0
                                                                                                                                                         
  CD8 change from BL (medican cells/µL)   138.0                      157.0                   31.5                   -3.00         -94.5     4.5          -78.5

Conclusions
===========

Greater increases in CD4+ and CD8+ counts were consistently achieved with MVC-containing regimens, compared to regimens without MVC, and persisted through at least 2 years of therapy in both TN and TE patients. These differences were independent of changes in HIV-1 RNA and are evident with multiple different MVC-containing regimens.
